Assembly Biosciences (ASMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -40,177 | -29,842 | -20,229 | -9,077 | -61,228 |
| Depreciation Amortization | -3,529 | -2,968 | -2,160 | -1,232 | -1,135 |
| Accounts receivable | 43 | 43 | 43 | N/A | 901 |
| Other Working Capital | -11,948 | -21,333 | -15,362 | -9,153 | 76,341 |
| Other Operating Activity | 4,494 | 3,390 | 2,242 | 1,098 | 7,864 |
| Operating Cash Flow | $-51,117 | $-50,710 | $-35,466 | $-18,364 | $22,743 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -28 | -28 | -28 | -14 | -231 |
| Purchase Of Investment | -90,501 | -49,605 | -34,893 | -3,714 | -133,922 |
| Sale Of Investment | 130,700 | 96,500 | 57,300 | 21,000 | 65,015 |
| Investing Cash Flow | $40,171 | $46,867 | $22,379 | $17,272 | $-69,138 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 29,449 | 12,454 | 12,454 | N/A | 13,818 |
| Financing Cash Flow | $29,449 | $12,454 | $12,454 | $N/A | $13,818 |
| Beginning Cash Position | 19,841 | 19,841 | 19,841 | 19,841 | 52,418 |
| End Cash Position | 38,344 | 28,452 | 19,208 | 18,749 | 19,841 |
| Net Cash Flow | $18,503 | $8,611 | $-633 | $-1,092 | $-32,577 |
| Free Cash Flow | |||||
| Operating Cash Flow | -51,117 | -50,710 | -35,466 | -18,364 | 22,743 |
| Capital Expenditure | -28 | -28 | -28 | -14 | -255 |
| Free Cash Flow | -51,145 | -50,738 | -35,494 | -18,378 | 22,488 |